Thesis
Merck's $6.7B acquisition of Terns closed on TERN-701's BTD-backed CML data; no investable public thesis remains
Terns was acquired by Merck on May 5, 2026, for $53.00 per share, driven by TERN-701's Phase 1/2 CARDINAL data in heavily pretreated Ph+ CML. No public equity remains; Terns is a wholly owned Merck subsidiary delisted from NASDAQ. The original thesis resolved at acquisition close, with TERN-601's metabolic program discontinued and TERN-801 unparnered.
Focus
Merck acquisition of Terns at $53/share closed May 5, 2026; TERN delisted
2026-05-05
Bull
Merck paid a substantial premium reflecting high conviction in TERN-701's differentiated profile, where ASH 2025 data showing 75% MMR at 24 weeks at the 320mg dose — 2-3x higher than asciminib — and a BTD granted in April 2026 validate the asset's pivotal potential; Merck's global commercial infrastructure and regulatory expertise could accelerate TERN-701 to approval faster than Terns could have as a standalone company.
Bear
TERN-701 remains in Phase 1/2 with an End of Phase 2 FDA interaction anticipated mid-2026, meaning pivotal trial design is not yet locked and approval is years away; Merck absorbed the asset at a ~$5.8B charge with clinical, regulatory, and commercial execution risk entirely on its shoulders, and any Phase 3 design misalignment with FDA or disappointing durability data could impair the asset's value.
Unlock the full thesis for TERN.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.